Table 5.
Antibiotic | Microbiological response | Clinical response | ||||
---|---|---|---|---|---|---|
Eradiction | Persistance | p value | Cure | Failure | P-value | |
Tigecycline | n = 10 | n = 2 | n = 9 | n = 3 | ||
fAUC/MIC ≥ 0.9 | 7 (70.0) | 2 (100) | NC | 6 (66.6) | 3 (100) | NC |
Meropenem | n = 4 | n = 0 | n = 3 | n = 1 | ||
fT > MIC ≥ 40% | 0 | 0 | NC | 0 | 0 | NC |
Both antibioticsa | n = 13 | n = 2 | n = 11 | n = 4 | ||
Achieved PD threshold | 7 (53.8) | 2 (100) | 0.486 | 6 (54.5) | 3 (75.0) | 0.604 |
fAUC/MIC free area under the curve/MIC, fT > MIC free time above the MIC, PD pharmacodynamic, NC not calculated
aPatient 4 received meropenem for study days 1–4, followed by tigecycline for study days 4–14; this patient is counted as exposure threshold achieved due to attainment of tigecycline PD target